Barra, 668 patient HCQ late treatment study: 11% lower mortality [p=1] https://c19p.org/barra
copied to clipboard
COVID-19 in hospitalized patients in 4 hospitals in San Isidro, Buenos Aires, Argentina
et al., medRxiv, doi:10.1101/2021.07.30.21261220 (Preprint)
Retrospective 668 hospitalized patients in Argentina, 18 treated with HCQ, not showing a significant difference in unadjusted results.
|
risk of death, 10.8% lower, RR 0.89, p = 1.00, treatment 2 of 18 (11.1%), control 81 of 650 (12.5%), NNT 74, unadjusted.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
This study is excluded in the after exclusion results of meta
analysis:
unadjusted results with no group details.
Barra et al., 7/31/2021, retrospective, Argentina, South America, preprint, 12 authors, average treatment delay 5.0 days.
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.